Search Within

Devika Gajria

Formats
  1. Meeting Abstract (19)
  2. Journal Article (12)
Groups
  1. Breast Medicine Service (31)
  2. Department of Medicine (31)
  3. Solid Tumor Oncology Division (31)
  4. Survivorship Research (26)
  5. Epidemiology and Biostatistics (22)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (20)

More Groups

People
  1. Clifford Hudis (16)
  2. Shanu Modi (15)
  3. Diana Lake (13)
  4. Shari Goldfarb (13)
  5. Sujata Patil (13)
  6. Larry Norton (12)

More People

Years
  1. 2024 (1)
  2. 2023 (1)
  3. 2022 (2)
  4. 2019 (2)
  5. 2018 (2)
  6. 2017 (1)

More Years

Publications
  1. Journal of Clinical Oncology (9)
  2. Cancer Research (8)
  3. Blood (2)
  4. Breast Cancer Research and Treatment (2)
  5. Clinical Breast Cancer (2)
  6. JAMA Dermatology (2)

More Publications

Publishers
  1. American Association for Cancer Research (9)
  2. American Society of Clinical Oncology (9)
  3. Elsevier Inc. (3)
  4. American Medical Association (2)
  5. American Society of Hematology (2)
  6. Springer (2)

More Publishers

Results (31)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I/II study of neratinib plus temsirolimus in HER2+ metastatic breast cancer reveals ongoing HER2 pathway dependence in many patients despite several lines of HER2 targeted therapy
    Meeting Abstract

    Gajria, D.; Modi, S.; Saura, C.; Sakr, R.; Solano, K.; Won, H.; Pannu, H.; Patil, S.; Lake, D.; Traina, T.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
    Journal Article

    Dang, C.; Iyengar, N.; Datko, F.; D'Andrea, G.; Theodoulou, M.; Dickler, M.; Goldfarb, S.; Lake, D.; Fasano, J.; Fornier, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase II feasibility study of paclitaxel (T) with trastuzumab (H) and lapatinib (L) for node-negative, HER2-positive breast cancer (BC)
    Meeting Abstract

    Iyengar, N. M.; Fornier, M. N.; Sugarman, S.; Theodoulou, M.; Troso-Sandoval, T. A.; D'Andrea, G.; Drullinsky, P.; Fasano, J.; Gajria, D.; Goldfarb, S. B.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Using (124)I-PU-H71 PET imaging to predict intratumoral concentration in patients on a phase I trial of PU-H71
    Meeting Abstract

    Gerecitano, J. F.; Modi, S.; Gajria, D.; Taldone, T.; Alpaugh, M.; DaGama, E. G.; Uddin, M.; Chiosis, G.; Lewis, J. S.; Larson, S. M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC)
    Meeting Abstract

    Datko, F. M.; D'Andrea, G.; Dickler, M. N.; Goldfarb, S. B.; Theodoulou, M.; Lake, D.; Fornier, M. N.; Modi, S.; Fasano, J.; Comen, E. A.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • ABT-888 plus bendamustine is safe and has shown preliminary efficacy in patients with lymphoma
    Meeting Abstract

    Gerecitano, J. F.; Schwartz, G. K.; Carvajal, R.; Fury, M.; Konner, J.; Hyman, D. M.; Gounder, M.; Gajria, D.; Teitcher, J.; Zhang, Z.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer with cardiac biomarker data
    Meeting Abstract

    Iyengar, N. M.; Datko, F. M.; D'Andrea, G.; Dickler, M. N.; Goldfarb, S.; Theodoulou, M.; Lake, D.; Fornier, M. N.; Modi, S.; Fasano, J.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors
    Journal Article

    Hudis, C.; Swanton, C.; Janjigian, Y. Y.; Lee, R.; Sutherland, S.; Lehman, R.; Chandarlapaty, S.; Hamilton, N.; Gajria, D.; Knowles, J.; more...
    Breast Cancer Research (2013)

    Fulltext@MSK | Save
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC)
    Meeting Abstract

    Datko, F. M.; D'Andrea, G.; Dickler, M. N.; Theodoulou, M.; Goldfarb, S. B.; Lake, D.; Fornier, M. N.; Modi, S.; Sklarin, N. T.; Comen, E. A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • IBL2001: Phase I/II study of a novel dose-dense schedule of oral indibulin for the treatment of metastastic breast cancer
    Meeting Abstract

    Traina, T. A.; Hudis, C.; Seidman, A.; Gajria, D.; Gonzalez, J.; Anthony, S. P.; Smith, D. A.; Chandler, J. C.; Jac, J.; Youssoufian, H.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save